ReviewHeart failure reviews2014
Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.
Review in Heart failure reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Challenges of Biomarker Application in Patients with Cardiorenal Syndrome.Biomedicines · 2026Review
- Review
- Combining cardiac and renal biomarkers to establish a clinical early prediction model for cardiac surgery-associated acute kidney injury: a prospective observational study.Journal of thoracic disease · 2024Article
- Development of a new miniaturized system for ultrafiltration.Heart failure reviews · 2024Review
- Measurement of Cardiac-Specific Biomarkers in the Emergency Department: New Insight in Risk Evaluation.International journal of molecular sciences · 2023Review
- The Relationship between the MAGGIC Score and Cardiorenal Syndrome in Patients with Acute Decompensated Heart Failure with Reduced Ejection Fraction.Acta Cardiologica Sinica · 2023Article
- Article
- New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy.International journal of molecular sciences · 2023Review
- Elevation of serum human epididymis protein 4 (HE4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) as predicting factors for the occurrence of acute kidney injury on chronic kidney disease: a single-center retrospective self-control study.Frontiers in pharmacology · 2023Article
- Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an under-diagnosed disease.Journal of clinical ultrasound : JCU · 2022Review
- Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Observational
- Accuracy of high-sensitive troponin depending on renal function for clinical outcome prediction in patients with acute heart failure.Heart and vessels · 2022Article
- Troponin T Elevation After Percutaneous Left Atrial Appendage Occlusion.Frontiers in cardiovascular medicine · 2021Article
- Article
- Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels.PloS one · 2018Article
- Troponin T elevation after permanent pacemaker implantation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2017Article
- Cardiac biomarkers are associated with maximum stage of acute kidney injury in critically ill patients: a prospective analysis.Critical care (London, England) · 2017Observational
- Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives.Journal of diabetes research · 2016Review
- Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection.Internal and emergency medicine · 2015Review
- Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, numerous biomarkers have been studied in heart failure to improve diagnostic accuracy and identify patients at higher risk. The overall outcome remains fairish despite improvements in therapy, with mean survival after first hospitalization, around 5 years. We therefore need surrogate end points to better understand the pathogenetic mechanisms of the disease, including interplays with other organs. The kidney plays an important role in the initiation and progression of HF, and around one-third of patients with HF show some degree of renal dysfunction. In addition, treatment for HF often worsens renal function, consequently to hemodynamic and clinical improvement do not correspond an effective improvement in HF prognosis. Association between HF and renal impairment (RI) is now classified as cardiorenal syndrome (CRS) pointing out the bidirectional nature of this vicious circle leading to a mutual and progressive damage of both organs. The clinicians can rely on circulating biomarkers that give insights into the underlying pathogenetic mechanisms and help in risk stratification. Recently, a multimarker strategy including biomarker tool to traditional risk scores has been purposed and applied: Although each biomarker provided incremental outcome benefit, the combination of multiple biomarkers should offer the greatest improvement in risk prediction. Natriuretic peptides (NP) and cardiac troponins (TN) are the two biomarkers most studied in this setting, probably because of their organ-specific nature. However, both NP and TN cutoffs in presence of renal dysfunction need to be revised and discussed in relation to age, gender and stage of RI. In this context, the biomarkers are a unique opportunity to elucidate pathophysiological mechanisms, tailor clinical management to the single patient and improve outcomes. Specific studies about the exact role of biomarkers as in HF as in CRS should be planned and considered for future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.